Compare Stocks: LIMN, NEUP, JSPR, and DYAI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYAI Dyadic International	$0.42 -0.8%	$0.58	$0.34 ▼ $1.60	$16.43M	0.96	179,234 shs	31,267 shs
JSPR Jasper Therapeutics	$0.47 -4.8%	$0.67	$0.32 ▼ $2.69	$15.71M	3.16	822,048 shs	435,734 shs
LIMN Liminatus Pharma	$3.34 -2.1%	$4.37	$3.27 ▼ $141.50	$4.48M	4.97	339,712 shs	17,333 shs
NEUP Neuphoria Therapeutics	$3.27 -3.7%	$3.72	$3.19 ▼ $17.90	$17.66M	0.75	90,635 shs	40,877 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYAI Dyadic International	+1.00%	-6.18%	-12.13%	-65.14%	-60.25%
JSPR Jasper Therapeutics	-10.70%	-11.52%	-24.94%	-28.38%	-79.35%
LIMN Liminatus Pharma	-1.16%	-7.84%	-1.73%	-40.44%	-95.16%
NEUP Neuphoria Therapeutics	+2.11%	-1.74%	-9.12%	-3.69%	-79.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYAI Dyadic International	$0.42 -0.8%	$0.58	$0.34 ▼ $1.60	$16.43M	0.96	179,234 shs	31,267 shs
JSPR Jasper Therapeutics	$0.47 -4.8%	$0.67	$0.32 ▼ $2.69	$15.71M	3.16	822,048 shs	435,734 shs
LIMN Liminatus Pharma	$3.34 -2.1%	$4.37	$3.27 ▼ $141.50	$4.48M	4.97	339,712 shs	17,333 shs
NEUP Neuphoria Therapeutics	$3.27 -3.7%	$3.72	$3.19 ▼ $17.90	$17.66M	0.75	90,635 shs	40,877 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYAI Dyadic International	+1.00%	-6.18%	-12.13%	-65.14%	-60.25%
JSPR Jasper Therapeutics	-10.70%	-11.52%	-24.94%	-28.38%	-79.35%
LIMN Liminatus Pharma	-1.16%	-7.84%	-1.73%	-40.44%	-95.16%
NEUP Neuphoria Therapeutics	+2.11%	-1.74%	-9.12%	-3.69%	-79.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYAI Dyadic International	2.00	Hold	$3.00	610.90% Upside
JSPR Jasper Therapeutics	2.38	Hold	$7.33	1,453.67% Upside
LIMN Liminatus Pharma	1.00	Sell	N/A	N/A
NEUP Neuphoria Therapeutics	1.67	Reduce	$7.00	114.40% Upside

Current Analyst Ratings Breakdown

Latest LIMN, NEUP, JSPR, and DYAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
9/3/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	NEUP Neuphoria Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/20/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/12/2026	DYAI Dyadic International	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$2.00
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$2.00
7/17/2026	JSPR Jasper Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYAI Dyadic International	$3.09M	5.47	N/A	N/A	$0.03 per share	14.07
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	($18.13) per share	N/A
NEUP Neuphoria Therapeutics	$1.17M	15.10	N/A	N/A	$4.55 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYAI Dyadic International	-$7.36M	-$0.23	N/A	N/A	N/A	-201.43%	-2,920.31%	-84.77%	11/11/2026 (Estimated)
JSPR Jasper Therapeutics	-$75.80M	-$1.59	N/A	N/A	N/A	N/A	-884.17%	-143.83%	11/9/2026 (Estimated)
LIMN Liminatus Pharma	-$10.21M	-$23.50	N/A	N/A	N/A	N/A	N/A	-256.58%	N/A
NEUP Neuphoria Therapeutics	-$13.45M	-$6.22	N/A	N/A	N/A	N/A	-38.31%	-28.92%	N/A

Latest LIMN, NEUP, JSPR, and DYAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	DYAI Dyadic International	-$0.03	N/A	N/A	N/A	$1.43 million	N/A
11/9/2026	Q3 2026	JSPR Jasper Therapeutics	-$0.08	N/A	N/A	N/A	$12.00 million	N/A
8/14/2026	Q2 2026	JSPR Jasper Therapeutics	-$0.2678	-$0.10	+$0.1678	-$0.10	N/A	N/A
8/12/2026	Q2 2026	DYAI Dyadic International	-$0.0350	-$0.06	-$0.0250	-$0.06	$1.03 million	$0.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYAI Dyadic International	N/A	1.65	1.65
JSPR Jasper Therapeutics	N/A	1.48	1.47
LIMN Liminatus Pharma	N/A	1.12	1.12
NEUP Neuphoria Therapeutics	N/A	27.83	27.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYAI Dyadic International	27.95%
JSPR Jasper Therapeutics	79.85%
LIMN Liminatus Pharma	N/A
NEUP Neuphoria Therapeutics	15.90%

Insider Ownership

Company	Insider Ownership
DYAI Dyadic International	20.90%
JSPR Jasper Therapeutics	3.90%
LIMN Liminatus Pharma	19.40%
NEUP Neuphoria Therapeutics	1.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYAI Dyadic International	5	40.06 million	31.69 million	Optionable
JSPR Jasper Therapeutics	22	33.28 million	31.98 million	Optionable
LIMN Liminatus Pharma	1	1.34 million	1.08 million	N/A
NEUP Neuphoria Therapeutics	8	5.41 million	5.33 million	N/A

LIMN, NEUP, JSPR, and DYAI Headlines

Recent News About These Companies

Neuphoria Therapeutics Inc. Reports Earnings Results for the Full Year Ended June 30, 2026

September 19, 2026 | marketscreener.comM

Neuphoria Therapeutics Inc Ordinary Shares NEUP

August 14, 2026 | morningstar.comM

Neuphoria Therapeutics Inc (NEUP)

August 8, 2026 | investing.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX

July 30, 2026 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC

July 28, 2026 | globenewswire.com

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

July 24, 2026 | businesswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

July 24, 2026 | prnewswire.com

Small cap movers: Scancell heads to Nasdaq as AIM's headcount falls to 612

July 24, 2026 | msn.com

Scancell to go public after winning reverse merger bid for troubled Neuphoria

July 24, 2026 | fiercebiotech.comF

Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing

July 24, 2026 | uk.finance.yahoo.com

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

July 23, 2026 | globenewswire.com

Neuphoria Therapeutics Stock Dividends | NASDAQ:NEUP | Benzinga

July 11, 2026 | benzinga.com

Merck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woes

July 3, 2026 | biospace.comB

Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms

July 1, 2026 | fiercebiotech.comF

MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership

July 1, 2026 | msn.com

Neuphoria Therapeutics Inc. Common Stock

June 27, 2026 | fxempire.comF

Neuphoria Therapeutics in Talks to Be Acquired by Scancell Holdings

June 27, 2026 | marketwatch.com

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

June 26, 2026 | globenewswire.com

HC Wainwright & Co. downgrades Neuphoria Therapeutics (NEUP)

May 17, 2026 | msn.com

Neuphoria Therapeutics (NEUP) price target increased by 38.22% to 13.77

May 14, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN, NEUP, JSPR, and DYAI Company Descriptions

Dyadic International NASDAQ:DYAI

$0.42 0.00 (-0.78%)

As of 03:48 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Jasper Therapeutics NASDAQ:JSPR

$0.47 -0.02 (-4.76%)

As of 03:46 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Liminatus Pharma NASDAQ:LIMN

$3.34 -0.07 (-2.05%)

As of 03:46 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Neuphoria Therapeutics NASDAQ:NEUP

$3.26 -0.13 (-3.69%)

As of 03:47 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIMN, NEUP, JSPR, and DYAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIMN, NEUP, JSPR, and DYAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIMN, NEUP, JSPR, and DYAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN, NEUP, JSPR, and DYAI Company Descriptions

Dyadic International NASDAQ:DYAI

Jasper Therapeutics NASDAQ:JSPR

Liminatus Pharma NASDAQ:LIMN

Neuphoria Therapeutics NASDAQ:NEUP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIMN, NEUP, JSPR, and DYAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIMN, NEUP, JSPR, and DYAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIMN, NEUP, JSPR, and DYAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN, NEUP, JSPR, and DYAI Company Descriptions

Dyadic International NASDAQ:DYAI

Jasper Therapeutics NASDAQ:JSPR

Liminatus Pharma NASDAQ:LIMN

Neuphoria Therapeutics NASDAQ:NEUP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools